Informa Group PLC
16 December 2002
16 December 2002
INFORMA Group Plc
Pre Close Period Statement
Informa is making a pre close period statement today ahead of its financial year
ending 31 December 2002.
Profitability in the second six months of 2002 is in line with our expectations.
Margin improvements resulting from continuing tight control over costs and price
increases above inflation for many of our products have countered the impact of
revenues which are below last year's level. Included in the profit and loss
account are restructuring costs for the year that are likely to be around £2.5m.
These will generate annualised savings in excess of £8m.
The group continues to be highly cash generative and enjoys a high ratio of
operating cash flow to operating profit conversion. This has enabled us to
reduce net debt levels this year and provides us with a firm basis to maintain
the dividend at the same level as 2001.
Subscription income, which accounts for around one third of total Group revenue,
has held firm with renewal rates on our electronic and hard copy business
information products continuing to average above 80%. This has underpinned the
strong performance from our Finance & Insurance division in particular where a
significant majority of the profit is derived from subscriptions. Our Law, Tax
and Commodities divisions, which also enjoy a high proportion of subscription
revenue, have also performed well.
Advertising income in our publications, which accounted for 13% of Group sales
in 2001, has run on average 16% below last year. This decline has particularly
affected the Maritime, Trade & Transport division where 36% of 2001's revenue
was derived from advertising. This division has performed more strongly in the
second half though its full year performance is still below 2001.
Life Sciences continues to be our fastest growing market as the division builds
successfully on its strong positions in the pharmaceutical and bio-technology
markets. We have seen growth in both our science publishing activity and the
related scientific events business.
Across our other areas of conference activity, delegate, sponsorship and
exhibition revenues have held up satisfactorily, enabling our strong second half
programme of events to deliver the expected profit. Although smaller niche
conferences continue to be challenging and have seen no improvement in revenues,
our larger events have shown good growth, particularly in sponsorship and
exhibition income. The outlook for our larger events in 2003 is promising with
sponsorship packages and exhibition space for 3GSM (February), Bluetooth (June)
and Drug Discovery Technology (August) already nearly sold out.
The Group continues to respond to market demand with new product launches. In
particular we have just run our first Bluetooth congress in the USA and will
stage an Asian version of the event in September 2003. We have also established
joint ventures with the Xinhua Financial Network in China and with Expomedia in
Russia, both of which look promising at this stage. In addition we will launch
two major new scientific journals - Bio-Processing International and Pre-Clinica
-- early next year as part of the continued development of the BioTechniques
scientific publishing division.
- ends -
For more information, please contact:
Jim Wilkinson, Finance Director, Informa Group plc Tel: 020 7017 4302
Catherine Lees/Zoe Sanders, Bell Pottinger Financial Tel: 020 7861 3877/3887
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.